JP2017503835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503835A5 JP2017503835A5 JP2016548111A JP2016548111A JP2017503835A5 JP 2017503835 A5 JP2017503835 A5 JP 2017503835A5 JP 2016548111 A JP2016548111 A JP 2016548111A JP 2016548111 A JP2016548111 A JP 2016548111A JP 2017503835 A5 JP2017503835 A5 JP 2017503835A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- cycloalkyl
- macular degeneration
- alkyl
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006660 (C3-C4) halocycloalkyl group Chemical group 0.000 claims 1
- 206010003226 Arteriovenous fistula Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 241001317099 Dystaxia Species 0.000 claims 1
- 206010052139 Eye oedema Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010072138 Limbal stem cell deficiency Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010043087 Tachyphylaxis Diseases 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 206010072959 birdshot chorioretinopathy Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000037818 intermediate age-related macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002969 morbid Effects 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 201000007714 retinoschisis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 *C(IN(*)C(c1c(*)c(I)c(*)cn1)=O)=O Chemical compound *C(IN(*)C(c1c(*)c(I)c(*)cn1)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930811P | 2014-01-23 | 2014-01-23 | |
| US61/930,811 | 2014-01-23 | ||
| PCT/US2015/012634 WO2015112831A1 (en) | 2014-01-23 | 2015-01-23 | Compositions and methods for treating ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503835A JP2017503835A (ja) | 2017-02-02 |
| JP2017503835A5 true JP2017503835A5 (cg-RX-API-DMAC7.html) | 2018-03-08 |
Family
ID=53681968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548111A Pending JP2017503835A (ja) | 2014-01-23 | 2015-01-23 | 眼球疾患治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160339005A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3096617A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017503835A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160108554A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106132201A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015209264A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2937349A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL246791A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016009331A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016133980A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015112831A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007265460B2 (en) | 2006-06-26 | 2011-03-03 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| NO2686520T3 (cg-RX-API-DMAC7.html) | 2011-06-06 | 2018-03-17 | ||
| MY204336A (en) | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| CN114890943A (zh) | 2013-11-15 | 2022-08-12 | 阿克比治疗有限公司 | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途 |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| KR20180036580A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물 |
| KR102252450B1 (ko) | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
| JP2020508073A (ja) * | 2017-02-27 | 2020-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 網膜分離症の非ヒト動物モデル |
| AR111190A1 (es) * | 2017-03-22 | 2019-06-12 | Genentech Inc | Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados |
| WO2018202865A1 (en) * | 2017-05-05 | 2018-11-08 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
| WO2018232227A1 (en) * | 2017-06-15 | 2018-12-20 | The Trustees Of Columbia University In The City Of New York | Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd |
| KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
| JP2021523222A (ja) * | 2018-05-01 | 2021-09-02 | チビ，インコーポレイティド | 網膜への薬剤の持続送達のための点眼剤および方法 |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| JP2021533148A (ja) * | 2018-08-21 | 2021-12-02 | カリフォルニア インスティチュート オブ テクノロジー | 非漏出性または最小漏出性の脈絡膜または網膜脈管再生 |
| JP7280353B2 (ja) * | 2018-11-02 | 2023-05-23 | キョンブク ナショナル ユニバーシティ インダストリー－アカデミック コーオペレーション ファウンデーション | 黄斑変性予防又は治療用組成物 |
| EP3875092B1 (en) | 2018-11-02 | 2025-11-19 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition for prevention or treatment of macular degeneration |
| WO2020098630A1 (en) * | 2018-11-14 | 2020-05-22 | Zhuhai Qiwei Bio-Technology Ltd. | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
| CN111308001B (zh) * | 2018-12-11 | 2024-11-29 | 上海市第一人民医院 | 人黄斑新生血管性疾病的代谢标记物及其应用 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| IL294873A (en) * | 2020-02-06 | 2022-09-01 | Perfuse Therapeutics Inc | Preparations for the treatment of eye diseases |
| EP4322985A4 (en) * | 2021-04-13 | 2025-02-19 | Unity Biotechnology, Inc. | METHODS OF TREATMENT OF RETINAL VASCULOPATHIES |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19650215A1 (de) * | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
| AU2007265460B2 (en) * | 2006-06-26 | 2011-03-03 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| US8865748B2 (en) * | 2011-06-06 | 2014-10-21 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| CN114890943A (zh) * | 2013-11-15 | 2022-08-12 | 阿克比治疗有限公司 | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途 |
-
2015
- 2015-01-23 JP JP2016548111A patent/JP2017503835A/ja active Pending
- 2015-01-23 RU RU2016133980A patent/RU2016133980A/ru not_active Application Discontinuation
- 2015-01-23 US US15/112,954 patent/US20160339005A1/en not_active Abandoned
- 2015-01-23 WO PCT/US2015/012634 patent/WO2015112831A1/en not_active Ceased
- 2015-01-23 CN CN201580015037.4A patent/CN106132201A/zh active Pending
- 2015-01-23 KR KR1020167022741A patent/KR20160108554A/ko not_active Withdrawn
- 2015-01-23 MX MX2016009331A patent/MX2016009331A/es unknown
- 2015-01-23 CA CA2937349A patent/CA2937349A1/en not_active Abandoned
- 2015-01-23 AU AU2015209264A patent/AU2015209264A1/en not_active Abandoned
- 2015-01-23 EP EP15740401.3A patent/EP3096617A4/en not_active Withdrawn
-
2016
- 2016-07-14 IL IL246791A patent/IL246791A0/en unknown